Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2030

Conditions
B-Cell Lymphoblastic Leukemia
Interventions
DRUG

Blinatumomab

Recruited patients will receive Blinatumomab since day 29 of induction for 14 days.

Trial Locations (4)

200127

RECRUITING

Shanghai Children's Medical center, Shanghai

230051

NOT_YET_RECRUITING

Anhui Provincial Children's Hospital, Hefei

315012

RECRUITING

Ningbo Women and Children's Hospital, Ningbo

350011

NOT_YET_RECRUITING

Fujian Children's Hospital, Fuzhou

All Listed Sponsors
collaborator

Fujian Children's Hospital

UNKNOWN

collaborator

Zhangzhou Affiliated Hospital of Fujian Medical University

OTHER

collaborator

Guizhou Provincial People's Hospital

OTHER

collaborator

The First Affiliated Hospital of Xiamen University

OTHER

collaborator

Dalian Women and Children's Medical Center

UNKNOWN

collaborator

The Third Xiangya Hospital of Central South University

OTHER

collaborator

Hunan Provincial People's Hospital

OTHER

collaborator

Ningbo Women & Children's Hospital

OTHER

collaborator

Anhui Provincial Children's Hospital

OTHER

collaborator

Jiangxi Province Children's Hospital

OTHER

collaborator

Yuying Children's Hospital of Wenzhou Medical University

OTHER

lead

Shanghai Jiao Tong University School of Medicine

OTHER